Optimized production of T cells expressing chimeric antigen receptors through PI3K inhibition with idelalisib

被引：0
|
作者：
Stock, S. [1 ]
Hoffmann, J. -M. [1 ]
Gern, U. [1 ]
Wang, L. [1 ]
Hueckelhoven, A. [1 ]
Neuber, B. [1 ]
Schubert, M. -L. [1 ]
Schmitt, A. [1 ]
Mueller-Tidow, C. [1 ]
Dreger, P. [1 ]
Schmitt, M. [1 ]
Sellner, L. [1 ]
机构：
[1] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V723
引用
收藏
页码：212 / 212
页数：1
相关论文
共 50 条
  • [1] PI3K Inhibition with Idelalisib for Optimized Production of Chimeric Antigen Receptor T Cells
    Stock, Sophia
    Hoffmann, Jean-Marc
    Wang, Lei
    Gong, Wenjie
    Huckelhoven, Angela
    Neuber, Brigitte
    Schubert, Maria-Luisa
    Gern, Ulrike
    Schmitt, Anita
    Mueller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    Sellner, Leopold
    BLOOD, 2017, 130
  • [2] Idelalisib-mediated PI3Kδ inhibition for optimized generation of CD19-specific chimeric antigen receptor T cells
    Stock, Sophia
    Schubert, Maria-Luisa
    Hoffmann, Jean-Marc
    Wang, Lei
    Gong, Wenjie
    Neuber, Brigitte
    Hueckelhoven, Angela
    Gern, Ulrike
    Schmitt, Anita
    Mueller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    Sellner, Leopold
    BONE MARROW TRANSPLANTATION, 2018, 53 : 119 - 120
  • [3] Imaging of T cells expressing chimeric antigen receptors
    Roszik, Janos
    Rabinovich, Brian
    Cooper, Laurence J. N.
    IMMUNOTHERAPY, 2011, 3 (12) : 1411 - 1414
  • [4] PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
    Zheng, Wenting
    O'Hear, Carol E.
    Alli, Rajshekhar
    Basham, Jacob H.
    Abdelsamed, Hossam A.
    Palmer, Lance E.
    Jones, Lindsay L.
    Youngblood, Ben
    Geiger, Terrence L.
    LEUKEMIA, 2018, 32 (05) : 1157 - 1167
  • [5] PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
    Wenting Zheng
    Carol E. O’Hear
    Rajshekhar Alli
    Jacob H. Basham
    Hossam A. Abdelsamed
    Lance E. Palmer
    Lindsay L. Jones
    Ben Youngblood
    Terrence L. Geiger
    Leukemia, 2018, 32 : 1157 - 1167
  • [6] PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
    Gopal, Ajay K.
    Kahl, Brad S.
    de Vos, Sven
    Wagner-Johnston, Nina D.
    Schuster, Stephen J.
    Jurczak, Wojciech J.
    Flinn, Ian W.
    Flowers, Christopher R.
    Martin, Peter
    Viardot, Andreas
    Blum, Kristie A.
    Goy, Andre H.
    Davies, Andrew J.
    Zinzani, Pier Luigi
    Dreyling, Martin
    Johnson, Dave
    Miller, Langdon L.
    Holes, Leanne
    Li, Daniel
    Dansey, Roger D.
    Godfrey, Wayne R.
    Salles, Gilles A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11): : 1008 - 1018
  • [7] Functional bifurcation in T cells expressing chimeric antigen receptors
    Chang, ZeNan L.
    Silver, Pamela A.
    Chen, Yvonne Y.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [8] THE PI3K DELTA SELECTIVE INHIBITOR, IDELALISIB, MODULATES CYTOKINE PRODUCTION IN INNATE IMMUNE CELLS STIMULATED THROUGH TOLL-LIKE RECEPTORS
    Grosmaire, L.
    Yahiaoui, A.
    Tannheimer, S.
    HAEMATOLOGICA, 2016, 101 : 417 - 417
  • [9] The PI3Kδ inhibitor, idelalisib, inhibits transcription and translation through PI3K/Akt pathway in mantle cell lymphoma
    Yang, Qingshan
    Chen, Lisa S.
    Neelapu, Sattva S.
    Gandhi, Varsha
    CANCER RESEARCH, 2014, 74 (19)
  • [10] The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
    Braun, Christiane
    Schlaweck, Sebastian
    Daecke, Solveig Nora
    Brossart, Peter
    Heine, Annkristin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (12) : 3693 - 3700
12345